Immunosuppressant binding antibodies and methods of obtaining and using same
The present invention relates among other things to antibodies that immunospecifically bind to at least one agent of interest (e.g., an immunosuppressive agent), methods for producing such antibodies, and immunoassays that employ said antibodies. Additionally, the present invention also relates to methods for selecting an antibody for use in a diagnostic immunoassay and methods for selecting an antigen for use in a diagnostic immunoassay. The present invention further relates to the improvement of antibody recognition of an active parent drug in the presence of one or more of its major metabolites.
1. A recombinant antibody, which specifically binds to tacrolimus and is expressed from DNA, which is extracted from the Chinese Hamster Ovary cell line 1-60-46 AM2 CHO 2-577 as deposited with the American Type Culture Collection under A.T.C.C. Accession No. PTA-7436.
2. A recombinant antibody, which specifically binds to tacrolimus and is produced by the Chinese Hamster Ovary cell line designated tacrolimus 1-60-46 AM2 CHO 2-577 as deposited with the American Type Culture Collection under A.T.C.C. Accession No. PTA-7436.
3. A recombinant antibody, which specifically binds to tacrolimus and is expressed from DNA, which is extracted from the Chinese Hamster Ovary cell line designated tacrolimus 1-60-46 AM2 CHO 1-1157 as deposited with the American Type Culture Collection under A.T.C.C. Accession No. PTA 7446.
4. A recombinant antibody, which specifically binds to tacrolimus and is produced by the Chinese Hamster Ovary cell line designated tacrolimus 1-60-46 AM2 CHO 1-1157 as deposited with the American Type Culture Collection under A.T.C.C. Accession No. PTA-7446.
5. An isolated recombinant antibody which specifically binds to tacrolimus, wherein said antibody has a variable heavy domain and a variable light domain, the variable heavy domain comprising a heavy chain complementary determining region (“CDR”) 1, a heavy chain CDR 2 and a heavy chain CDR 3, the variable light domain comprising a light chain CDR 1, a light chain CDR 2 and a light chain CDR 3, wherein
(a) Heavy Chain CDR 1 has an amino acid sequence of: Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Gly-Met-Ser (SEQ ID NO: 2);
(b) Heavy Chain CDR 2 has an amino acid sequence having a formula of: Thr-Ile-Ser-Ser-Gly-Gly-Ala-Trp-Thr-Phe (SEQ ID NO: 16);
(c) Heavy Chain CDR 3 has an amino acid sequence of: Gln-Thr-Asp-Gly-Tyr-Ser-Trp-Phe-Pro-Tyr (SEQ ID NO: 6);
(d) Light Chain CDR 1 has an amino acid sequence having a formula of: Lys-Ser-Ser-Gln-Gly-Leu-Val-His-Ser-Thr-Gly-Asn-Thr-Phe-Leu-Glu (SEQ ID NO: 22);
(e) Light Chain CDR 2 has an amino acid sequence having the formula of: Lys-Ile-Ser-Asn-Arg-Phe-Ser (SEQ ID NO: 11); and
(f) Light Chain CDR 3 has an amino acid sequence having a formula of: Phe-Gln-Gly-Ser-His-Ala-Pro-Leu-Thr (SEQ ID NO: 23).
6. An isolated recombinant antibody which specifically binds to tacrolimus, wherein said antibody has a variable heavy domain and a variable light domain, the variable heavy domain comprising a heavy chain complementary determining region (“CDR”) 1, a heavy chain CDR 2 and a heavy chain CDR 3, the variable light domain comprising a light chain CDR 1, a light chain CDR 2 and a light chain CDR 3, wherein
(a) Heavy Chain CDR 1 has an amino acid sequence of: Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Gly-Met-Ser (SEQ ID NO: 2);
(b) Heavy Chain CDR 2 has an amino acid sequence having a formula of: Thr-Ile-Ser-Ser-Gly-Gly-Ala-Trp-Thr-Phe (SEQ ID NO: 16);
(c) Heavy Chain CDR 3 has an amino acid sequence of: Gln-Thr-Asp-Gly-Tyr-Ser-Trp-Phe-Pro-Tyr (SEQ ID NO: 6);
(d) Light Chain CDR 1 has an amino acid sequence having a formula of: Lys-Ser-Ser-Gln-Gly-Leu-Val-His-Ser-Thr-Gly-Asn-Thr-Phe-Leu-Glu (SEQ ID NO: 22);
(e) Light Chain CDR 2 has an amino acid sequence having the formula of: Lys-Ile-Ser-Asn-Arg-Phe-Ser (SEQ ID NO: 11);
(f) Light Chain CDR 3 has an amino acid sequence having a formula of: Phe-Gln-Gly-Ser-His-Ala-Pro-Leu-Thr (SEQ ID NO: 23);
(g) Heavy Chain framework region FR1 has an amino acid sequence having a formula of: Glu-Val-Glu-Leu-Val-Glu-Ser-Gly-Gly-Asp-Leu-Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser (SEQ ID NO: 1);
(h) Heavy Chain framework region FR2 has an amino acid sequence having a formula of: Trp-Val-Arg-Gln-Thr-Pro-Asp-Lys-Arg-Leu-Glu-Trp-Val-Ala (SEQ ID NO: 3);
(i) Heavy Chain framework region FR3 has an amino acid sequence having a formula of: Tyr-Pro-Asp-Ser-Val-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Lys-Asn-Thr-Leu-Ser-Leu-Gln-Met-Ser-Ser-Leu-Lys-Ser-Ala-Asp-Thr-Ala-Met-Tyr-Tyr-Cys-Ser-Arg (SEQ ID NO: 5);
(j) Heavy Chain framework region FR4 has an amino acid sequence having a formula of: Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ala (SEQ ID NO: 7);
(k) Light Chain framework region FR1 has an amino acid sequence having a formula of: Asp-Val-Leu-Met-Thr-Gln-Thr-Pro-Leu-Ser-Leu-Pro-Val-Ser-Leu-Gly-Asp-Gln-Ala-Ser-Ile-Ser-Cys (SEQ ID NO: 8);
(l) Light Chain framework region FR2 has an amino acid sequence having a formula of: Trp-Phe-Leu-Gln-Lys-Pro-Gly-Gln-Ser-Pro-Lys-Leu-Leu-Ile-Tyr (SEQ ID NO: 10);
(m) Light Chain framework region FR3 has an amino acid sequence having a formula of: Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-Lys-Ile-Ser-Arg-Val-Glu-Ser-Glu-Asp-Leu-Gly-Val-Tyr-Tyr-Cys (SEQ ID NO: 12); and
(n) Light Chain framework region FR4 has an amino acid sequence having a formula of: Phe-Gly-Ala-Gly-Thr-Lys-Leu-Glu-Leu-Lys-Arg-Ala (SEQ ID NO: 14).
7. An isolated recombinant antibody which specifically binds to tacrolimus, wherein said antibody has a variable heavy domain and a variable light domain,
the variable heavy domain comprising an amino acid sequence having a formula of: Glu-Val-Glu-Leu-Val-Glu-Ser-Gly-Gly-Asp-Leu-Val-Lys-Pro-Gly-Gly-Ser-Leu-Lys-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Gly-Met-Ser-Trp-Val-Arg-Gln-Thr-Pro-Asp-Lys-Arg-Leu-Glu-Trp-Val-Ala-Thr-Ile-Ser-Ser-Gly-Gly-Ala-Trp-Thr-Phe-Tyr-Pro-Asp-Ser-Val-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ala-Lys-Asn-Thr-Leu-Ser-Leu-Gln-Met-Ser-Ser-Leu-Lys-Ser-Ala-Asp-Thr-Ala-Met-Tyr-Tyr-Cys-Ser-Arg-Gln-Thr-Asp-Gly-Tyr-Ser-Trp-Phe-Pro-Tyr-Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ala-Ser-Ala-Lys-Thr-Thr-Ala-Pro-Ser-Val-Tyr-Pro-Leu-Ala-Pro-Val-Cys-Gly-Asp-Thr-Thr-Gly-Ser-Ser-Val-Thr-Leu-Gly-Cys-Leu-Val-Lys-Gly-Tyr-Phe-Pro-Glu-Pro-Val-Thr-Leu-Thr-Trp-Asn-Ser-Gly-Ser-Leu-Ser-Ser-Gly-Val-His-Thr-Phe-Pro-Ala-Val-Leu-Gln-Ser-Asp-Leu-Tyr-Thr-Leu-Ser-Ser-Ser-Val-Thr-Val-Thr-Ser-Ser-Thr-Trp-Pro-Ser-Gln-Ser-Ile-Thr-Cys-Asn-Val-Ala-His-Pro-Ala-Ser-Ser-Thr-Lys-Val-Asp-Lys-Lys-Ile-Glu-Pro-Arg-Gly-Pro-Thr-Ile-Lys-Pro-Cys-Pro-Pro-Cys-Lys-Cys-Pro-Ala-Pro-Asn-Leu-Leu-Gly-Gly-Pro-Ser-Val-Phe-Ile-Phe-Pro-Pro-Lys-Ile-Lys-Asp-Val-Leu-Met-Ile-Ser-Leu-Ser-Pro-Ile-Val-Thr-Cys-Val-Val-Val-Asp-Val-Ser-Glu-Asp-Asp-Pro-Asp-Val-Gln-Ile-Ser-Trp-Phe-Val-Asn-Asn-Val-Glu-Val-His-Thr-Ala-Gln-Thr-Gln-Thr-His-Arg-Glu-Asp-Tyr-Asn-Ser-Thr-Leu-Arg-Val-Val-Ser-Ala-Leu-Pro-Ile-Gln-His-Gln-Asp-Trp-Met-Ser-Gly-Lys-Glu-Phe-Lys-Cys-Lys-Val-Asn-Asn-Lys-Asp-Leu-Pro-Ala-Pro-Ile-Glu-Arg-Thr-Ile-Ser-Lys-Pro-Lys-Gly-Ser-Val-Arg-Ala-Pro-Gln-Val-Tyr-Val-Leu-Pro-Pro-Pro-Glu-Glu-Glu-Met-Thr-Lys-Lys-Gln-Val-Thr-Leu-Thr-Cys-Met-Val-Thr-Asp-Phe-Met-Pro-Glu-Asp-Ile-Tyr-Val-Glu-Trp-Thr-Asn-Asn-Gly-Lys-Thr-Glu-Leu-Asn-Tyr-Lys-Asn-Thr-Glu-Pro-Val-Leu-Asp-Ser-Asp-Gly-Ser-Tyr-Phe-Met-Tyr-Ser-Lys-Leu-Arg-Val-Glu-Lys-Lys-Asn-Trp-Val-Glu-Arg-Asn-Ser-Tyr-Ser-Cys-Ser-Val-Val-His-Glu-Gly-Leu-His-Asn-His-His-Thr-Thr-Lys-Ser-Phe-Ser-Arg-Thr-Pro-Gly-Lys (SEQ ID NO: 40)
and the variable light domain comprising an amino acid sequence having a formula of: Asp-Val-Leu-Met-Thr-Gln-Thr-Pro-Leu-Ser-Leu-Pro-Val-Ser-Leu-Gly-Asp-Gln-Ala-Ser-Ile-Ser-Cys-Lys-Ser-Ser-Gln-Gly-Leu-Val-His-Ser-Thr-Gly-Asn-Thr-Phe-Leu-Glu-Trp-Phe-Leu-Gln-Lys-Pro-Gly-Gln-Ser-Pro-Lys-Leu-Leu-Ile-Tyr-Lys-Ile-Ser-Asn-Arg-Phe-Ser-Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-Lys-Ile-Ser-Arg-Val-Glu-Ser-Glu-Asp-Leu-Gly-Val-Tyr-Tyr-Cys-Phe-Gln-Gly-Ser-His-Ala-Pro-Leu-Thr-Phe-Gly-Ala-Gly-Thr-Lys-Leu-Glu-Leu-Lys-Arg-Ala-Ser-Ala-Asp-Ala-Ala-Pro-Thr-Val-Ser-Ile-Phe-Pro-Pro-Ser-Ser-Glu-Gln-Leu-Thr-Ser-Gly-Gly-Ala-Ser-Val-Val-Cys-Phe-Leu-Asn-Asn-Phe-Tyr-Pro-Lys-Asp-Ile-Asn-Val-Lys-Trp-Lys-Ile-Asp-Gly-Ser-Glu-Arg-Gln-Asn-Gly-Val-Leu-Asn-Ser-Trp-Thr-Asp-Gln-Asp-Ser-Lys-Asp-Ser-Thr-Tyr-Ser-Met-Ser-Ser-Thr-Leu-Thr-Leu-Thr-Lys-Asp-Glu-Tyr-Glu-Arg-His-Asn-Ser-Tyr-Thr-Cys-Glu-Ala-Thr-His-Lys-Thr-Ser-Thr-Ser-Pro-Ile-Val-Lys-Ser-Phe-Asn-Arg-Asn-Glu-Cys (SEQ ID NO: 42).